Nuvelo (Nasdaq: NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CharlieS who wrote (1)	8/6/1997 8:46:00 AM
From: CharlieS	of 286

To all 1995 article from Genetic Engineering discussing the Gene Screening from Hyseq. Hyseq (Sunnyvale, CA) recently announced the ability to read 64,000 bases in a single reaction. "The significance for discovery of genes is that there will be a lot less subcloning required and we will be able to look at much larger pieces of the genome," says Lewis S. Gruber, president and CEO of Hyseq. "With respect to diagnostics, we can look at multiple genesothose donit have to be 64,000 contiguous bases." Entire article at: enews.com Another 1994 article discussing collaborations. Genome Firms Lure Pharmaceutical Giants into Lucrative Collaborations The dozen or so genome companies that have sprouted up during the past few years envision revolutionary advances in medical diagnostics and therapeutics based on the identification and elucidation of genes that play a role in human disease processes. These companies are laying the foundation for the commercialization of their proprietary gene mapping and sequencing technologies: setting up their laboratories; wooing prominent scientists from academia; defining their strategic goals and differentiating themselves from the pack. Entire Article at: dc.enews.com Charlie

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next